Lauren Sciences
Lauren Sciences is dedicated to solving the major medical challenge in treating central nervous system (CNS) diseases by enabling therapeutic agents to cross the blood-brain barrier (BBB). Their breakthrough V-Smart® Platform allows non-invasive, triple-targeted CNS delivery of non-BBB penetrant therapeutic agents, including nucleic acids, antibodies, biologics, and small molecules. The company’s pipeline includes V-Smart® Nanomedicines in development for various CNS indications such as ALS, Parkinson’s Disease, Alzheimer’s Disease, Neuro-HIV, Glioblastoma, and Chronic Pain. They collaborate with pharmaceutical companies to develop proprietary therapeutic agents, aiming to significantly improve patient outcomes by enabling treatments currently unavailable due to BBB, PK, bioavailability, toxicity, or invasiveness.
Industries
Nr. of Employees
small (1-50)
Lauren Sciences
New York, New York, United States, North America
Products
CNS-targeted nanocarrier platform
A non-invasive, multi-targeted nanocarrier platform designed to facilitate transport of therapeutics across the blood–brain barrier to enable treatment of CNS diseases.
CNS-targeted nanomedicines (development pipeline)
Pipeline of nanomedicine candidates under development for multiple CNS indications, including neurodegenerative diseases and CNS oncology.
CNS-targeted nanocarrier platform
A non-invasive, multi-targeted nanocarrier platform designed to facilitate transport of therapeutics across the blood–brain barrier to enable treatment of CNS diseases.
CNS-targeted nanomedicines (development pipeline)
Pipeline of nanomedicine candidates under development for multiple CNS indications, including neurodegenerative diseases and CNS oncology.
Services
Contract development of CNS-targeted nanomedicines
Collaborative development services to formulate and advance nanomedicine candidates that incorporate partners' proprietary therapeutic agents for CNS indications under confidentiality arrangements.
Contract development of CNS-targeted nanomedicines
Collaborative development services to formulate and advance nanomedicine candidates that incorporate partners' proprietary therapeutic agents for CNS indications under confidentiality arrangements.
Expertise Areas
- Targeted CNS drug delivery
- Nanomedicine formulation and development
- Lipid chemistry and polymer/supramolecular chemistry for drug delivery
- Preclinical neuroscience research
Key Technologies
- Nanocarrier-based CNS delivery
- Lipid-based nanocarriers
- Polymer-based nanocarriers
- Microencapsulation